This inventor holds 1 USPTO granted patent. Top assignee: Shanghai Meizer Pharmaceuticals Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Fengjun Luo and BTK-Targeted Degradation Research.
Introduction
Fengjun Luo is an inventor based in Shanghai, China, associated with Shanghai Meizer Pharmaceuticals Co., Ltd. His listed patent concerns a compound designed to target and degrade Bruton's tyrosine kinase (BTK), a protein linked to certain diseases.
Latest Patents
Luo is associated with 1 patent, titled “Compound for Targeted Degradation of BTK and Anti-Tumour Use Thereof.” The invention describes preparing and screening a series of compounds, evaluating their ability to inhibit and degrade BTK, and identifying a compound with promising drug-like properties. The compound is proposed for treating diseases associated with BTK activity or expression.
Career Highlights
The available information connects Luo’s work to pharmaceutical research at Shanghai Meizer Pharmaceuticals Co., Ltd. His patent focuses on targeted protein degradation as a potential approach to treating BTK-related diseases.
Collaborations
Luo’s listed coworker is Yongzhi Shu. Their association is noted in connection with the BTK-targeting patent.
Conclusion
Fengjun Luo’s recorded patent highlights research into a BTK-targeting compound and its potential anti-tumour and therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile